BGI Genomics Co., Ltd. (300676.SZ)
CNY 49.18
(-0.06%)
CNY 49.18
(-0.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 92.9 Million CNY | -88.43% |
| 2022 | 802.76 Million CNY | -45.07% |
| 2021 | 1.46 Billion CNY | -30.08% |
| 2020 | 2.09 Billion CNY | 656.43% |
| 2019 | 276.33 Million CNY | -28.53% |
| 2018 | 386.64 Million CNY | -2.88% |
| 2017 | 398.09 Million CNY | 19.66% |
| 2016 | 332.69 Million CNY | 26.93% |
| 2015 | 262.09 Million CNY | 832.05% |
| 2014 | 28.12 Million CNY | -79.3% |
| 2013 | 135.88 Million CNY | 66.25% |
| 2012 | 81.73 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 5.79 Million CNY | -53.26% |
| 2024 Q3 | -142.36 Million CNY | -2555.75% |
| 2024 Q1 | 12.4 Million CNY | -44.99% |
| 2023 Q3 | 18.6 Million CNY | 79.01% |
| 2023 FY | 92.9 Million CNY | -88.43% |
| 2023 Q1 | 41.21 Million CNY | -25.85% |
| 2023 Q2 | 10.39 Million CNY | -74.78% |
| 2023 Q4 | 22.54 Million CNY | 21.17% |
| 2022 FY | 802.76 Million CNY | -45.07% |
| 2022 Q4 | 55.58 Million CNY | -60.7% |
| 2022 Q3 | 141.44 Million CNY | -48.66% |
| 2022 Q2 | 275.48 Million CNY | -16.62% |
| 2022 Q1 | 330.41 Million CNY | 598.52% |
| 2021 Q2 | 561.03 Million CNY | 6.87% |
| 2021 Q4 | 47.3 Million CNY | -85.59% |
| 2021 FY | 1.46 Billion CNY | -30.08% |
| 2021 Q3 | 328.21 Million CNY | -41.5% |
| 2021 Q1 | 524.98 Million CNY | 185.36% |
| 2020 FY | 2.09 Billion CNY | 656.43% |
| 2020 Q1 | 140.01 Million CNY | 2137.77% |
| 2020 Q2 | 1.51 Billion CNY | 979.46% |
| 2020 Q3 | 1.05 Billion CNY | -30.28% |
| 2020 Q4 | -615.01 Million CNY | -158.36% |
| 2019 Q4 | 6.25 Million CNY | -91.32% |
| 2019 FY | 276.33 Million CNY | -28.53% |
| 2019 Q3 | 72.1 Million CNY | -27.73% |
| 2019 Q2 | 99.77 Million CNY | 1.61% |
| 2019 Q1 | 98.19 Million CNY | 47.69% |
| 2018 FY | 386.64 Million CNY | -2.88% |
| 2018 Q1 | 100.74 Million CNY | 17.61% |
| 2018 Q2 | 106.99 Million CNY | 6.2% |
| 2018 Q3 | 112.41 Million CNY | 5.06% |
| 2018 Q4 | 66.48 Million CNY | -40.86% |
| 2017 Q1 | 94.41 Million CNY | 24.89% |
| 2017 Q2 | 96.64 Million CNY | 2.36% |
| 2017 Q3 | 121.36 Million CNY | 25.58% |
| 2017 Q4 | 85.66 Million CNY | -29.41% |
| 2017 FY | 398.09 Million CNY | 19.66% |
| 2016 FY | 332.69 Million CNY | 26.93% |
| 2016 Q4 | 75.59 Million CNY | -29.95% |
| 2016 Q3 | 107.92 Million CNY | 45.71% |
| 2016 Q2 | 74.06 Million CNY | -1.39% |
| 2016 Q1 | 75.1 Million CNY | 0.0% |
| 2015 FY | 262.09 Million CNY | 832.05% |
| 2015 Q1 | 37.82 Million CNY | 0.0% |
| 2015 Q2 | 37.82 Million CNY | 0.0% |
| 2014 FY | 28.12 Million CNY | -79.3% |
| 2013 FY | 135.88 Million CNY | 66.25% |
| 2012 FY | 81.73 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 307.46 Million CNY | 69.785% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion CNY | 95.412% |
| Dirui Industrial Co.,Ltd. | 275.58 Million CNY | 66.29% |
| Beijing Strong Biotechnologies, Inc. | 523.74 Million CNY | 82.262% |
| Medicalsystem Biotechnology Co., Ltd. | 256.55 Million CNY | 63.789% |
| Maccura Biotechnology Co.Ltd | 312.61 Million CNY | 70.283% |
| Guangzhou Wondfo Biotech Co.,Ltd | 487.62 Million CNY | 80.948% |
| Guangdong Hybribio Biotech Co.,Ltd. | 140.47 Million CNY | 33.866% |
| Amoy Diagnostics Co., Ltd. | 261.48 Million CNY | 64.472% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -141.59 Million CNY | 165.612% |